Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Sees Unusually-High Trading Volume – Here’s Why

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) shares saw unusually-strong trading volume on Tuesday . 504,555 shares traded hands during mid-day trading, an increase of 195% from the previous session’s volume of 171,004 shares.The stock last traded at $27.00 and had previously closed at $26.71.

Analysts Set New Price Targets

LKFT has been the subject of a number of recent analyst reports. Zacks Research upgraded Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Royal Bank Of Canada decreased their target price on Lakefront Biotherapeutics American Depositary Shares from $28.00 to $26.00 and set a “sector perform” rating for the company in a research note on Tuesday, August 11th. Weiss Ratings upgraded Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, August 27th. Morgan Stanley cut their price target on Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 11th. Finally, TD Cowen assumed coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, August 21st. They issued a “buy” rating for the company. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $30.67.

Lakefront Biotherapeutics American Depositary Shares Trading Up 4.6%

The firm’s 50-day moving average is $28.39 and its 200-day moving average is $29.10. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of -19.81 and a beta of 0.28.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its quarterly earnings data on Monday, August 10th. The biotechnology company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.97) by $1.01. The business had revenue of $15.47 million for the quarter, compared to analyst estimates of $7.29 million. Analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -1.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. ABC Arbitrage SA purchased a new stake in Lakefront Biotherapeutics American Depositary Shares in the 1st quarter valued at $382,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Lakefront Biotherapeutics American Depositary Shares during the 1st quarter worth $248,000. QRG Capital Management Inc. grew its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 21.9% in the 1st quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock worth $591,000 after acquiring an additional 3,535 shares in the last quarter. Finally, Madison Avenue Partners LP grew its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 0.8% in the 4th quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock worth $72,371,000 after acquiring an additional 17,394 shares in the last quarter. Institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.